August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
August 29th 2025
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
August 22nd 2025
New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.
August 22nd 2025
STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.
August 21st 2025
First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.
Rates of Vaccinations in Children See Decline During COVID-19 Pandemic
April 16th 2021The ongoing pandemic has caused a severe decrease in childhood vaccinations, while some rates have recovered, others have not and clinicians are urging caregivers to have their children receive their shots.
Read More
CDC’s ACIP Decides Not to Vote on Recommendations for Johnson & Johnson COVID-19 Vaccine
April 14th 2021The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met today to discuss the blood clots’ issue and offered guidance on heparin usage in these cases.
Read More
“Out of Abundance of Caution” Johnson & Johnson COVID-19 Vaccine is Paused
April 13th 2021In a press conference this morning, leadership of the FDA and CDC discussed why they made the decision on this vaccine and announced an ACIP meeting will be held tomorrow to review the data from the adverse events.
Read More
2 Commerce Drive
Cranbury, NJ 08512